title: Evaluation of complement factor 5 variants as genetic risk factors for the development of advanced fibrosis in chronic hepatitis C infection.
abstract: OBJECTIVE
  Intercross studies in inbred mice susceptible or resistant to liver fibrosis revealed complement factor 5 as a quantitative trait gene associated with the development of fibrosis. In 277 patients with hepatitis C, two C5 SNPs, rs17611 and rs2300929, have been associated with advanced fibrosis.
  
  
  METHODS
  We investigated the association of these C5 SNPs with advanced fibrosis in 1435 HCV infected patients and in 1003 patients with other liver diseases. We performed genotyping with melting curve analysis using fluorescence resonance energy transfer probes in the LightCycler.
  
  
  RESULTS
  The defined high-risk genotypes (AA and TT) and alleles (A and T) were not associated with advanced fibrosis in HCV patients when Chi square testing and logistic regression analysis were applied (rs17611A 0.45 in F0-1 vs. 0.43 in F2-4, P=0.31; rs2300929T 0.91 F0-1 and 0.91 in F2-4, P=0.82). In the group of patients with liver diseases other than HCV we neither found an association of the C5 SNPs with advanced fibrosis nor an overrepresentation of the SNPs in patients with cirrhosis.
  
  
  CONCLUSIONS
  We found no evidence that these C5 SNPs are genetic risk factors for the development of advanced fibrosis in chronic HCV infection or other chronic liver diseases.
authors.affiliation: Medizinische Klinik mit Schwerpunkt Hepatologie und Gastroenterologie, Charité - Universitätsmedizin Berlin, Campus Virchow-Klinikum, Germany.
authors.forename: Juliane
authors.initials: J
authors.lastname: Halangk
authors.forename: Christoph
authors.initials: C
authors.lastname: Sarrazin
authors.forename: Konrad
authors.initials: K
authors.lastname: Neumann
authors.forename: Gero
authors.initials: G
authors.lastname: Puhl
authors.forename: Tobias
authors.initials: T
authors.lastname: Mueller
authors.forename: Gerlinde
authors.initials: G
authors.lastname: Teuber
authors.forename: Hartwig
authors.initials: H
authors.lastname: Klinker
authors.forename: Holger
authors.initials: H
authors.lastname: Hinrichsen
authors.forename: Peter
authors.initials: P
authors.lastname: Buggisch
authors.forename: Olfert
authors.initials: O
authors.lastname: Landt
authors.forename: Viola
authors.initials: V
authors.lastname: Weich
authors.forename: Alexandra
authors.initials: A
authors.lastname: Bergk
authors.forename: Bertram
authors.initials: B
authors.lastname: Wiedenmann
authors.forename: Peter
authors.initials: P
authors.lastname: Neuhaus
authors.forename: Thomas
authors.initials: T
authors.lastname: Berg
authors.forename: Heiko
authors.initials: H
authors.lastname: Witt
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015331:Cohort Studies; D003182:Complement C5 / Q000235:genetics*; D005060:Europe; D005260:Female; D005787:Gene Frequency / Q000235:genetics; D020022:Genetic Predisposition to Disease / Q000235:genetics; D005838:Genotype; D005858:Germany; D006239:Haplotypes / Q000235:genetics; D019698:Hepatitis C, Chronic / Q000150:complications*; D006801:Humans; D008103:Liver Cirrhosis / Q000453:epidemiology* / Q000209:etiology / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D020641:Polymorphism, Single Nucleotide / Q000235:genetics*; D012307:Risk Factors
chemical_list: D003182:Complement C5